Sinovac Biotech Ltd Cash Flow Conversion Efficiency
Sinovac Biotech Ltd cash flow conversion efficiency. Based on the latest financial reports, Sinovac Biotech Ltd (SVA) has a cash flow conversion efficiency ratio of 0.012x as of December 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($146.01 Million) by net assets ($12.02 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sinovac Biotech Ltd (2000–2025)
Cash flow conversion efficiency of Sinovac Biotech Ltd from 2000 to 2025. This chart illustrates how Sinovac Biotech Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Sinovac Biotech Ltd (SVA) stock price for real-time trading data and today's change.
Sinovac Biotech Ltd Cash Flow Conversion Ratio Explained
Sinovac Biotech Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sinovac Biotech Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sinovac Biotech Ltd ranked by their cash flow conversion efficiency. Also see market value of Sinovac Biotech Ltd for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Companhia de Saneamento do Paraná - SANEPAR
SA:SAPR3
|
0.045x |
|
Century Iron And Steel Industrial Co Ltd
TW:9958
|
0.057x |
|
Xiamen Comfort Science&Technology Group Co Ltd
SHE:002614
|
0.000x |
|
Dongguan Mentech Optical & Magnetic Co Ltd
SHE:002902
|
-0.090x |
|
Sungho Electronics Corp
KQ:043260
|
-0.033x |
|
Wowprime Corp
TW:2727
|
0.197x |
|
New York Mortgage Trust Inc
NASDAQ:NYMT
|
0.028x |
|
Basellandschaftliche Kantonalbank
SW:BLKB
|
-0.313x |
Annual Cash Flow Conversion Efficiency for Sinovac Biotech Ltd (2000–2025)
The table below shows the annual cash flow conversion efficiency of Sinovac Biotech Ltd from 2000 to 2025. Review SVA FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.40 Billion | $-510.49 Million | -0.080x | -1342.69% |
| 2024-12-31 | $10.29 Billion | $-56.89 Million | -0.006x | -162.68% |
| 2023-12-31 | $12.02 Billion | $106.02 Million | 0.009x | +114.54% |
| 2022-12-31 | $12.71 Billion | $-770.75 Million | -0.061x | -105.48% |
| 2021-12-31 | $13.88 Billion | $15.35 Billion | 1.106x | +158.56% |
| 2020-12-31 | $1.12 Billion | $479.31 Million | 0.428x | +285.70% |
| 2019-12-31 | $352.19 Million | $39.07 Million | 0.111x | +307.75% |
| 2018-12-31 | $291.93 Million | $7.94 Million | 0.027x | -94.10% |
| 2017-12-31 | $129.67 Million | $59.76 Million | 0.461x | +486.55% |
| 2016-12-31 | $129.67 Million | $-15.46 Million | -0.119x | -486.47% |
| 2015-12-31 | $136.50 Million | $4.21 Million | 0.031x | +143.17% |
| 2014-12-31 | $141.73 Million | $-10.13 Million | -0.071x | -284.07% |
| 2013-12-31 | $143.64 Million | $5.58 Million | 0.039x | +130.91% |
| 2012-12-31 | $129.44 Million | $-16.25 Million | -0.126x | -230.93% |
| 2011-12-31 | $145.30 Million | $13.94 Million | 0.096x | +199.25% |
| 2010-12-31 | $147.76 Million | $-14.28 Million | -0.097x | -116.86% |
| 2009-12-31 | $84.47 Million | $48.41 Million | 0.573x | +192.64% |
| 2008-12-31 | $53.64 Million | $10.50 Million | 0.196x | +49.30% |
| 2007-12-31 | $32.90 Million | $4.32 Million | 0.131x | +270.93% |
| 2006-12-31 | $21.31 Million | $-1.64 Million | -0.077x | -12.10% |
| 2005-12-31 | $16.51 Million | $-1.13 Million | -0.068x | +30.71% |
| 2004-12-31 | $15.56 Million | $-1.54 Million | -0.099x | +37.57% |
| 2003-12-31 | $10.89 Million | $-1.72 Million | -0.158x | +72.89% |
| 2002-12-31 | $99.44K | $-58.05K | -0.584x | -180.57% |
| 2001-12-31 | $-682.96K | $-494.80K | 0.724x | 0.00% |
| 2000-12-31 | $-682.96K | $-494.80K | 0.724x | -- |
About Sinovac Biotech Ltd
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza;… Read more